Jubilant Pharmova Limited has made a regulatory disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
The disclosure concerns Jubilant Generics Limited, a wholly-owned subsidiary of the company, which has received a Show Cause Notice from the Joint Commissioner, CGST Division, Roorkee. The notice proposes demand of GST, interest, and penalty for the Financial Year 2020-21 to 2021-2022.
Key Details:
- The event occurred on August 27, 2026, at 12:35 PM (IST)
- The notice was issued by the Joint Commissioner, CGST Division, Roorkee
- The period under scrutiny is Financial Years 2020-21 to 2021-2022
- The notice proposes demands for GST, interest, and penalty
- Financial impact has not been quantified in the disclosure
Company Response:
The company is in the process of taking necessary action to file a detailed reply before the Joint Commissioner, CGST Division, Roorkee in response to the Show Cause Notice.
The document has been simultaneously posted on the company's website at www.jubilantpharmova.com.